Non-GAAP research and development expenses for Q1 2011 had been $28.1 million, in comparison to $20.3 million for Q1 2010. The increase in R&D expenditures primarily reflected the growth of the Company’s clinical trial programs. Non-GAAP offering, general and administrative expenses for Q1 2011 had been $57.8 million, in comparison to $44.9 million for Q1 2010. The increase in non-GAAP SG&A expenditures primarily reflected costs from the expansion of the Company’s commercial operations in new geographies. First One fourth GAAP Financial Outcomes: Alexion reported GAAP net gain of $26.8 million, or $0.28 per share, for Q1 2011, including a negative after-tax impact of $6.9 million, or $0.07 per share, from costs related to the Taligen Therapeutics and Orphatec Pharmaceuticals acquisitions during the quarter, in comparison to Q1 2010 GAAP net income of $20.9 million, or $0.23 per share.Nevertheless, after a full year, no factor in function was discovered between the two groups. And, the participants reported no improvement in discomfort after one month, three months or one year of therapy, the researchers said. People with lower back pain have a tendency to progress quickly, and the physical therapy helped them make it happen just a little quicker, said lead researcher Julie Fritz, a professor of physical therapy at the University of Utah. But the difference between your improvement that is included with period and the improvement that is included with therapy is not a huge difference, she said. The very best treatment for low back pain is to stay active and exercise despite the fact that it’s painful, Fritz said. The goal is to maintain people moving to greatly help them recover, and that often happens without assistance, she added.